BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

20 Dec 2025, 08:16 by Jessica Moore · The Cerbat Gem

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). In a filing disclosed on December 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in BioCryst Pharmaceuticals stock on November 13th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 11/26/2025.
Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/26/2025.
Purchased $1,001 – $15,000 in shares of First Watch Restaurant Group (NASDAQ:FWRG) on 11/26/2025.
Purchased $1,001 – $15,000 in shares of TKO Group (NYSE:TKO) on 11/26/2025.
Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 11/24/2025.
Sold $1,001 – $15,000 in shares of Stifel Financial (NYSE:SF) on 11/24/2025.
Purchased $1,001 – $15,000 in shares of Logan Energy (CVE:LGN) on 11/24/2025.
Sold $1,001 – $15,000 in shares of Primoris Services (NASDAQ:PRIM) on 11/24/2025.
Purchased $15,001 – $50,000 in shares of LandBridge (NYSE:LB) on 11/21/2025.
Purchased $50,001 – $100,000 in shares of LandBridge (NYSE:LB) on 11/20/2025.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $7.41 on Friday. The company’s fifty day moving average price is $7.17 and its 200-day moving average price is $8.14. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.31. The firm has a market capitalization of $1.56 billion, a P/E ratio of -148.20, a PEG ratio of 0.70 and a beta of 0.91.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.01). The company had revenue of $159.40 million for the quarter, compared to analyst estimates of $162.91 million. BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.BioCryst Pharmaceuticals’s revenue for the quarter was up 36.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.07) earnings per share. Equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in BCRX. Deerfield Management Company L.P. raised its position in BioCryst Pharmaceuticals by 159.4% during the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after acquiring an additional 7,477,000 shares during the period. Arrowstreet Capital Limited Partnership raised its position in shares of BioCryst Pharmaceuticals by 2,103.7% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company’s stock worth $38,336,000 after purchasing an additional 4,084,403 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of BioCryst Pharmaceuticals by 25,631.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company’s stock worth $32,441,000 after purchasing an additional 3,606,566 shares during the last quarter. Millennium Management LLC lifted its stake in BioCryst Pharmaceuticals by 382.6% in the 1st quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock valued at $28,597,000 after buying an additional 3,022,769 shares in the last quarter. Finally, Qube Research & Technologies Ltd boosted its holdings in BioCryst Pharmaceuticals by 152.3% in the 2nd quarter. Qube Research & Technologies Ltd now owns 2,373,489 shares of the biotechnology company’s stock worth $21,266,000 after buying an additional 1,432,824 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 19,770 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $7.65, for a total transaction of $151,240.50. Following the completion of the transaction, the insider owned 345,476 shares of the company’s stock, valued at $2,642,891.40. This represents a 5.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders sold 161,680 shares of company stock worth $1,164,401. 5.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on BCRX shares. Zacks Research downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Needham & Company LLC dropped their price objective on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. JMP Securities boosted their target price on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the company a “market outperform” rating in a research note on Wednesday, October 15th. Cantor Fitzgerald increased their price target on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday, October 15th. Finally, HC Wainwright raised their price target on shares of BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $19.50.

Get Our Latest Research Report on BCRX

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About BioCryst Pharmaceuticals

(Get Free Report)

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.